Go to content
UR Home

The oral Ca/calmodulin‐dependent kinase II inhibitor RA608 improves contractile function and prevents arrhythmias in heart failure

URN to cite this document:
DOI to cite this document:
Mustroph, Julian ; Drzymalski, Marzena ; Baier, Maria ; Pabel, Steffen ; Biedermann, Alexander ; Memmel, Bernadette ; Durczok, Melanie ; Neef, Stefan ; Sag, Can Martin ; Floerchinger, Bernhard ; Rupprecht, Leopold ; Schmid, Christof ; Zausig, York ; Bégis, Guillaume ; Briand, Veronique ; Ozoux, Marie‐Laure ; Tamarelle, Dorothee ; Ballet, Veronique ; Janiak, Philip ; Beauverger, Philippe ; Maier, Lars S. ; Wagner, Stefan
Date of publication of this fulltext: 12 Jan 2021 15:01


Aims Excessive activation of Ca/calmodulin-dependent kinase II (CaMKII) is of critical importance in heart failure (HF) and atrial fibrillation. Unfortunately, lack of selectivity, specificity, and bioavailability have slowed down development of inhibitors for clinical use. We investigated a novel CaMKII delta/CaMKII-selective, ATP-competitive, orally available CaMKII inhibitor (RA608) on right ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: daten@ur.de
0941 943 -4239

Contact persons